NEW YORK, Jan 16, 2026, 09:12 EST — Premarket
- PainReform (PRFX) jumped roughly 13% in premarket action, following a close near 82 cents on Thursday.
- The Israel-based company announced it has rebranded as PRF Technologies Ltd but will retain its Nasdaq ticker symbol, PRFX.
- The company described the change as a step away from focusing solely on a pain-therapy program, branching into drug delivery and solar-analytics sectors.
PainReform Ltd shares rose in premarket trading on Friday following the company’s announcement that it has rebranded as PRF Technologies Ltd. The microcap firm said the new name signals an expansion beyond its initial focus on pain therapy.
The name change is significant because PainReform was mainly evaluated based on a single clinical program. Now, it’s pitching investors on a broader portfolio, which could shift what moves the stock on any given day.
The timing couldn’t be more telling, as traders rush toward clean “story” catalysts in thinly traded stocks. But whether this momentum lasts once the market opens is another matter entirely.
The company submitted the announcement to the U.S. Securities and Exchange Commission on Thursday, filing a Form 6-K.
“This name change reflects how fundamentally the Company has evolved,” Executive Chairman and interim Chief Executive Officer Ehud Geller said in the release. “We are no longer defined by a single program,” he added.
The company said it is moving forward with PRF-110, a non-opioid, extended-release treatment aimed at post-surgical pain. This formulation releases medication gradually, reducing the need for multiple doses.
It also highlighted LayerBio, its majority-owned unit working on OcuRing-K, a “dropless” ocular therapy designed to manage pain and inflammation following cataract surgery. The term “dropless” describes treatments intended to cut down or eliminate the need for weeks of post-op eye drops.
Alongside that is DeepSolar, an analytics firm specializing in utility-scale solar assets. The company said it provides technical due diligence and is developing a forecasting product through Nvidia’s Connect Program. It has also entered early commercial deployment.
A rebrand won’t fix the tough realities. Clinical timelines still run late, pilot programs don’t always convert into contracts, and small firms frequently hit funding hurdles well before steady revenue arrives.
Traders will be focused on whether the early pop holds once regular trading kicks off at 9:30 a.m. EST, and if the company delivers clearer milestones in upcoming updates—be it on customers, clinical plans, or financing.
